{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:48:14Z","timestamp":1790534894650,"version":"4.1.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"French PIA","award":["ANR-15-IDEX-04-LUE"],"award-info":[{"award-number":["ANR-15-IDEX-04-LUE"]}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-15-RHU-0004"],"award-info":[{"award-number":["ANR-15-RHU-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ERA-Net-CVD","award":["01KL1706"],"award-info":[{"award-number":["01KL1706"]}]},{"name":"CVON She-PREDICTS","award":["2017-21"],"award-info":[{"award-number":["2017-21"]}]},{"name":"CVON2016-Early HFPEF","award":["2015-10"],"award-info":[{"award-number":["2015-10"]}]},{"name":"European Union Commission\u2019s Seventh Framework programme","award":["305507"],"award-info":[{"award-number":["305507"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR\u201015\u2010RHU\u20100004"],"award-info":[{"award-number":["ANR\u201015\u2010RHU\u20100004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Asymptomatic patients with coronary artery disease (CAD), hypertension and\/or type 2 diabetes mellitus (T2DM) are at greater risk of developing heart failure (HF). Fibrosis, leading to myocardial and vascular dysfunction, might be an important pathway of progression. The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The HOMAGE trial is a prospective, randomised, open-label, blinded endpoint (PROBE) study comparing spironolactone (up to 50\u2009mg\/day) and standard care over 9\u2009months in people with clinical risk factors for developing HF, including hypertension, CAD and T2DM, and elevated plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP, 125 to 1000\u2009ng\/L) or B-type natriuretic peptide (BNP, 35 to 280\u2009ng\/L). Exclusion criteria included left ventricular ejection fraction &amp;lt;\u200945%, atrial fibrillation, severe renal dysfunction, or treatment with loop diuretics. The primary endpoint was the interaction between change in serum concentrations of procollagen type III N-terminal propeptide (PIIINP) and treatment with spironolactone according to median plasma concentrations of galectin-3 at baseline. For the 527 participants enrolled, median (interquartile range) age was 73 (69\u201379) years, 135 (26%) were women, 412 (78%) had hypertension, 377 (72%) CAD, and 212 (40%) T2DM. At baseline, medians (interquartile ranges) were for left ventricular ejection fraction 63 (58\u201367)\u2009%, for left atrial volume index 31 (26-37)\u2009mL\/m2, for plasma NT-proBNP 214 (137\u2013356)\u2009ng\/L, for serum PIIINP 3.9 (3.1\u20135.0)\u2009ng\/mL, and for galectin-3 16.1 (13.5\u201319.7)\u2009ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The HOMAGE trial will provide insights on the effect of spironolactone on pathways that might drive progression to HF.<\/jats:p>\n                    <jats:p>Clinical Trial Registration: ClinicalTrials.gov \u00a0NCT02556450.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.1716","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T22:09:51Z","timestamp":1579212591000},"page":"1711-1723","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Effects of Spironolactone on Serum Markers of Fibrosis in People at High Risk of Developing Heart Failure: Rationale, Design and Baseline Characteristics of a Proof-of-Concept, Randomised, Precision-Medicine, Prevention Trial. The Heart OMics in AGing (HOMAGE) Trial"],"prefix":"10.1093","volume":"22","author":[{"given":"Pierpaolo","family":"Pellicori","sequence":"first","affiliation":[{"name":"Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d\u2019Investigations Cliniques Plurith\u00e9matique, INSERM 1433, CHRU de Nancy,Institut Lorrain du Coeur et des Vaisseaux, FCRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Mariottoni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cortona Hospital , Arezzo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fozia Z.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Manchester Heart Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job","family":"Verdonschot","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Collier","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe J.","family":"Cuthbert","sequence":"additional","affiliation":[{"name":"Department of Academic Cardiology, Castle Hill Hospital, Hull York Medical School (at University of Hull) , Kingston upon Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Petutschnigg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]},{"name":"DZHK (German Center of Cardiovascular Research), Partner Site Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blerim","family":"Mujaj","sequence":"additional","affiliation":[{"name":"Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d\u2019Investigations Cliniques Plurith\u00e9matique, INSERM 1433, CHRU de Nancy,Institut Lorrain du Coeur et des Vaisseaux, FCRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Program of Cardiovascular Diseases, CIMA Universidad de Navarra and IdiSNA , Pamplona ,","place":["Spain"]},{"name":"CIBERCV, Carlos III Institute of Health , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Academic Cardiology, Castle Hill Hospital, Hull York Medical School (at University of Hull) , Kingston upon Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cosmi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cortona Hospital , Arezzo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Staessen","sequence":"additional","affiliation":[{"name":"Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center , Maastricht ,","place":["The Netherlands"]},{"name":"Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"The Netherlands Heart Institute , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latini","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d\u2019Investigations Cliniques Plurith\u00e9matique, INSERM 1433, CHRU de Nancy,Institut Lorrain du Coeur et des Vaisseaux, FCRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d\u2019Investigations Cliniques Plurith\u00e9matique, INSERM 1433, CHRU de Nancy,Institut Lorrain du Coeur et des Vaisseaux, FCRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[{"name":"Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"2026011721371607200_ejhf1716-bib-0001","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","article-title":"Heart failure drug treatment","volume":"393","author":"Rossignol","year":"2019","journal-title":"Lancet"},{"key":"2026011721371607200_ejhf1716-bib-0002","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jacc.2019.03.471","article-title":"Prevention or procrastination for heart failure? Why we need a universal definition of heart failure","volume":"73","author":"Cleland","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0003","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"2026011721371607200_ejhf1716-bib-0004","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/eurheartj\/ehp420","article-title":"N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population","volume":"31","author":"Linssen","year":"2010","journal-title":"Eur Heart J"},{"key":"2026011721371607200_ejhf1716-bib-0006","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"2026011721371607200_ejhf1716-bib-0007","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/eurjhf\/hft001","article-title":"N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluation of the Evolution of New-Heart Failure Study (SCREEN-HF)","volume":"15","author":"McGrady","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jama.297.2.169","article-title":"N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease","volume":"297","author":"Bibbins-Domingo","year":"2007","journal-title":"JAMA"},{"key":"2026011721371607200_ejhf1716-bib-0009","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/eurjhf\/hfs052","article-title":"Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy","volume":"14","author":"Mureddu","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0010","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ejhf.312","article-title":"Searching for new mechanisms of myocardial fibrosis with diagnostic and\/or therapeutic potential","volume":"17","author":"Heymans","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0011","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/01.CIR.0000140973.60992.9A","article-title":"Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis","volume":"110","author":"Querejeta","year":"2004","journal-title":"Circulation"},{"key":"2026011721371607200_ejhf1716-bib-0012","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/CIRCHEARTFAILURE.110.960716","article-title":"Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy","volume":"4","author":"Krum","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0013","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0014","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","author":"Ravassa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/CIRCHEARTFAILURE.111.962027","article-title":"The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study","volume":"4","author":"Barasch","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0016","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/aje\/kwu067","article-title":"Fibrosis-related biomarkers and risk of total and cause-specific mortality: the Cardiovascular Health Study","volume":"179","author":"Agarwal","year":"2014","journal-title":"Am J Epidemiol"},{"key":"2026011721371607200_ejhf1716-bib-0017","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.jacc.2015.04.026","article-title":"Circulating biomarkers of myocardial fibrosis: the need for a reappraisal","volume":"65","author":"L\u00f3pez","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0018","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0019","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/HYPERTENSIONAHA.115.05876","article-title":"Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension","volume":"66","author":"Mart\u00ednez-Mart\u00ednez","year":"2015","journal-title":"Hypertension"},{"key":"2026011721371607200_ejhf1716-bib-0020","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0021","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ejhf.1406","article-title":"Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0022","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"key":"2026011721371607200_ejhf1716-bib-0023","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011721371607200_ejhf1716-bib-0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721371607200_ejhf1716-bib-0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"2026011721371607200_ejhf1716-bib-0026","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011721371607200_ejhf1716-bib-0027","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"2026011721371607200_ejhf1716-bib-0028","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","article-title":"Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"2026011721371607200_ejhf1716-bib-0029","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00392-017-1157-3","article-title":"Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER study","volume":"107","author":"Ferreira","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0031","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00392-019-01500-3","article-title":"Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials","volume":"109","author":"Stienen","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0032","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone","volume":"54","author":"Mak","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0033","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction Trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"2026011721371607200_ejhf1716-bib-0034","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/heartjnl-2012-303329","article-title":"Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade","volume":"99","author":"Kosmala","year":"2013","journal-title":"Heart"},{"key":"2026011721371607200_ejhf1716-bib-0035","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026011721371607200_ejhf1716-bib-0036","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2018-313182","article-title":"Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure","volume":"105","author":"Ferreira","year":"2018","journal-title":"Heart"},{"key":"2026011721371607200_ejhf1716-bib-0037","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF","volume":"73","author":"Zile","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0038","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002551","article-title":"Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the Prospective Comparison of ARNI With ARB on Management of Heart Failure with Preserved Ejection Fraction study","volume":"9","author":"Zile","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0039","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"2026011721371607200_ejhf1716-bib-0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"2026011721371607200_ejhf1716-bib-0041","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0042","article-title":"2009 Focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Hunt","year":"2009","journal-title":"Circulation"},{"key":"2026011721371607200_ejhf1716-bib-0043","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/thx.2007.081208","article-title":"Minimum clinically important improvement for the incremental shuttle walking test","volume":"63","author":"Singh","year":"2008","journal-title":"Thorax"},{"key":"2026011721371607200_ejhf1716-bib-0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167582","article-title":"Diastolic left ventricular function in relation to urinary and serum collagen biomarkers in a general population","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"2026011721371607200_ejhf1716-bib-0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0046","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jacc.2006.08.062","article-title":"Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES","volume":"49","author":"Persson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026011721371607200_ejhf1716-bib-0047","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/eurjhf\/hfs049","article-title":"Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study","volume":"14","author":"Cleland","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721371607200_ejhf1716-bib-0048","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011721371607200_ejhf1716-bib-0049","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721371607200_ejhf1716-bib-0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"de Boer","year":"2012","journal-title":"J Intern Med"},{"key":"2026011721371607200_ejhf1716-bib-0051","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"2026011721371607200_ejhf1716-bib-0052","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80\u2009years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"2026011721371607200_ejhf1716-bib-0053","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","journal-title":"JAMA"},{"key":"2026011721371607200_ejhf1716-bib-0054","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"2026011721371607200_ejhf1716-bib-0055","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026011721371607200_ejhf1716-bib-0056","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.1716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.1716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/9\/1711\/66111789\/eurjhf_22_9_1711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/9\/1711\/66111789\/eurjhf_22_9_1711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:39:46Z","timestamp":1768703986000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/22\/9\/1711\/8384630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,1,16]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1716","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,1,16]]},"assertion":[{"value":"2019-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}